---
$id: https://graph.org.ai/products/commodity/51201817
$type: Product
source: UNSPSC
code: "51201817"
title: "Pidotimod"
class: "51201800"
classTitle: "Immunostimulating agents"
family: "51200000"
familyTitle: "Immunomodulating drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Pidotimod

**UNSPSC Code**: 51201817
**Class**: [Immunostimulating agents](Immunostimulating agents.mdx)
**Family**: [Immunomodulating drugs](../Immunomodulating drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an immunostimulant with the molecular formula C9H12N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 785363R681, chemically known as 4-thiazolidinecarboxylic acid, 3-((5-oxo-2-pyrrolidinyl)carbonyl)-, (r-(r*,s*))- but generally known as pidotimod, which bears US NIH Compound Identifier 65944. European Medicines Agency schedules Pidotimod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09826MIG. The term PIDOTIMOD is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules pidotimod in its Anatomical Therapeutic Chemical (ATC) Classification. PIDOTIMOD is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pidotimod under HS 29341000 and SITC 51579. As of Q4 2014, PIDOTIMOD remains the US FDA Preferred Term for this commodity. Pidotimod bears US NLM identifiers UMLS ID C0081002 and NCI Concept Code C76686. SMILES: S1CC(N(C(=O)C2NC(=O)CC2)C1)C(=O)O.

